Mar 24, 2013 by Dave WilliamsonIs Eli Lilly's Management Charting the Right Course?Is management at Eli Lilly an asset or a liability?
Mar 22, 2013 by Dave WilliamsonWhy Anacor Cannot Be ContainedThis pharmaceutical company is unstoppable.
Mar 22, 2013 by Dave WilliamsonGilead Keeps on BuildingOne more step towards Gilead's HIV treatment empire.
Mar 22, 2013 by Dave WilliamsonWhy Celgene's Management Is a StrengthWhy Celgene's top brass is a big asset.
Mar 21, 2013 by Dave WilliamsonDoes Eli Lilly's Future Depend on Acquisitions?Could Eli Lilly's next move be a home-run acquisition?
Mar 21, 2013 by Dave WilliamsonWhat Acadia Investors Need to Know About This Stock's Pop TodayAcadia shares jumped today. Here are the key reasons why that you need to know.
Mar 20, 2013 by Dave WilliamsonWhy Melanoma Should Fear HerpesAmgen hunts cancer with a modified herpes virus.
Mar 20, 2013 by Dave WilliamsonValeant Continues to DevourThe pharma continues to gobble up smaller business snacks.
Mar 19, 2013 by Dave WilliamsonDown 60%: Affymax Cuts to the BoneRemember, investors, don't count those mysterious biotech pops before actual news confirms it.
Mar 19, 2013 by Dave WilliamsonEli Lilly: Strong Sustainable Dividend?Eli Lilly investors know its strong dividend yield, but can the company maintain it?
Mar 18, 2013 by Dave WilliamsonThe Demise of a Multibillion-Dollar Drug Class?Is this the end for this entire class of drugs?
Mar 18, 2013 by Dave WilliamsonShould Incyte Investors Be Panicked?Should you be panicked by this biotech sell-off?
Mar 14, 2013 by Dave WilliamsonWall Street Is Out of Patience With This BiotechCancer drug hopeful Geron gets hit with a downgrade.
Mar 14, 2013 by Dave WilliamsonWhy Chinese Biotech Sinovac SoaredChinese biotech soars on groundbreaking vaccine passing a Phase 3 trial.
Mar 14, 2013 by Dave WilliamsonPicking Up the Pieces of Shattered SpectrumAfter a massive plunge, is Spectrum Pharmaceuticals on sale?
Mar 12, 2013 by Dave WilliamsonWhy Bears Are Devouring SpectrumAn after-hours press release has investors panicked.
Mar 12, 2013 by Dave WilliamsonFebruary's Biggest Biotech Loser Bounces BackPeregrine's roller coaster ride is as exciting for investors as it is nauseating.
Mar 11, 2013 by Dave WilliamsonBreakdown of This Biotech MassacreWhy Wall Street ran red with this biotech's blood today.
Mar 8, 2013 by Dave WilliamsonSteer Clear of Affymax's Mysterious PopThis is a rocket ride you want no part of.
